{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-203755","form_type":"8-K","ticker":"KYMR","cik":"0001815442","company_name":"Kymera Therapeutics, Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.629914+00:00","generated_at":"2026-05-31T08:29:54.627881+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kymera prices $225M offering of common stock and pre-funded warrants","bullets":["Selling 2,002,313 shares at $40.75 and 3,519,159 pre-funded warrants at $40.7499.","Net proceeds estimated at ~$246.5M after underwriting discounts and expenses.","Underwriters exercised 30-day option to purchase additional 828,220 shares in full.","Proceeds to advance preclinical and clinical degrader programs and for working capital.","Existing cash plus offering proceeds expected to fund operations into mid 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-203755","json":"https://secwatch.observer/filing/0001193125-24-203755.json","markdown":"https://secwatch.observer/filing/0001193125-24-203755.md","text":"https://secwatch.observer/filing/0001193125-24-203755.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/0001193125-24-203755-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815442/000119312524203755/d846843d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:29:54.627881+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}